JP7542912B2 - Ｈｔｔリプレッサーおよびその使用 - Google Patents
Ｈｔｔリプレッサーおよびその使用 Download PDFInfo
- Publication number
- JP7542912B2 JP7542912B2 JP2021540305A JP2021540305A JP7542912B2 JP 7542912 B2 JP7542912 B2 JP 7542912B2 JP 2021540305 A JP2021540305 A JP 2021540305A JP 2021540305 A JP2021540305 A JP 2021540305A JP 7542912 B2 JP7542912 B2 JP 7542912B2
- Authority
- JP
- Japan
- Prior art keywords
- zfp
- mhtt
- cells
- protein
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 193
- 210000004027 cell Anatomy 0.000 claims description 156
- 108091007916 Zinc finger transcription factors Proteins 0.000 claims description 104
- 102000038627 Zinc finger transcription factors Human genes 0.000 claims description 104
- 230000014509 gene expression Effects 0.000 claims description 95
- 239000013598 vector Substances 0.000 claims description 88
- 208000023105 Huntington disease Diseases 0.000 claims description 77
- 102000040430 polynucleotide Human genes 0.000 claims description 72
- 108091033319 polynucleotide Proteins 0.000 claims description 72
- 239000002157 polynucleotide Substances 0.000 claims description 72
- 239000000203 mixture Substances 0.000 claims description 58
- 210000002569 neuron Anatomy 0.000 claims description 47
- 210000001577 neostriatum Anatomy 0.000 claims description 43
- 239000013608 rAAV vector Substances 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 33
- 210000004556 brain Anatomy 0.000 claims description 30
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims description 16
- 101150043003 Htt gene Proteins 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 208000016285 Movement disease Diseases 0.000 claims description 6
- 101710185494 Zinc finger protein Proteins 0.000 description 114
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 114
- 102000004169 proteins and genes Human genes 0.000 description 108
- 235000018102 proteins Nutrition 0.000 description 106
- 238000000034 method Methods 0.000 description 90
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 description 75
- 230000004568 DNA-binding Effects 0.000 description 69
- 150000007523 nucleic acids Chemical class 0.000 description 67
- 239000002773 nucleotide Substances 0.000 description 65
- 125000003729 nucleotide group Chemical group 0.000 description 65
- 101710163270 Nuclease Proteins 0.000 description 64
- 102000039446 nucleic acids Human genes 0.000 description 64
- 108020004707 nucleic acids Proteins 0.000 description 64
- 108020004999 messenger RNA Proteins 0.000 description 59
- 108700028369 Alleles Proteins 0.000 description 44
- 238000003776 cleavage reaction Methods 0.000 description 44
- 230000007017 scission Effects 0.000 description 44
- 108020004414 DNA Proteins 0.000 description 42
- 239000013607 AAV vector Substances 0.000 description 40
- 230000027455 binding Effects 0.000 description 40
- 230000004927 fusion Effects 0.000 description 39
- 108090000765 processed proteins & peptides Proteins 0.000 description 39
- 102000004196 processed proteins & peptides Human genes 0.000 description 37
- 229920001184 polypeptide Polymers 0.000 description 36
- 108091033409 CRISPR Proteins 0.000 description 31
- 108020001507 fusion proteins Proteins 0.000 description 29
- 102000037865 fusion proteins Human genes 0.000 description 29
- 238000010453 CRISPR/Cas method Methods 0.000 description 28
- 108091023040 Transcription factor Proteins 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- 102000040945 Transcription factor Human genes 0.000 description 27
- -1 dCas Proteins 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 23
- 241000699670 Mus sp. Species 0.000 description 23
- 108700019146 Transgenes Proteins 0.000 description 23
- 239000013603 viral vector Substances 0.000 description 22
- 230000003612 virological effect Effects 0.000 description 21
- 201000010099 disease Diseases 0.000 description 20
- 230000004913 activation Effects 0.000 description 19
- 238000001727 in vivo Methods 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 238000013518 transcription Methods 0.000 description 18
- 230000035897 transcription Effects 0.000 description 18
- 239000011701 zinc Substances 0.000 description 18
- 229910052725 zinc Inorganic materials 0.000 description 18
- 230000001105 regulatory effect Effects 0.000 description 17
- 230000001629 suppression Effects 0.000 description 17
- 238000001415 gene therapy Methods 0.000 description 16
- 238000010459 TALEN Methods 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 238000012546 transfer Methods 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 13
- 210000000130 stem cell Anatomy 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 12
- 241000193996 Streptococcus pyogenes Species 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 11
- 108020005004 Guide RNA Proteins 0.000 description 11
- 238000011529 RT qPCR Methods 0.000 description 11
- 108091027544 Subgenomic mRNA Proteins 0.000 description 11
- 108091028113 Trans-activating crRNA Proteins 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 9
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 9
- 102000004533 Endonucleases Human genes 0.000 description 9
- 108010042407 Endonucleases Proteins 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- 230000006780 non-homologous end joining Effects 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- 241000700605 Viruses Species 0.000 description 8
- 210000003169 central nervous system Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000001177 retroviral effect Effects 0.000 description 8
- 241000701161 unidentified adenovirus Species 0.000 description 8
- 241000702421 Dependoparvovirus Species 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000006471 dimerization reaction Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000005090 green fluorescent protein Substances 0.000 description 7
- 230000010354 integration Effects 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 108010077544 Chromatin Proteins 0.000 description 6
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- 101001072037 Homo sapiens cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000002146 bilateral effect Effects 0.000 description 6
- 210000003483 chromatin Anatomy 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 230000002950 deficient Effects 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000005782 double-strand break Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 238000010362 genome editing Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 230000007659 motor function Effects 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 6
- 230000032965 negative regulation of cell volume Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 125000006850 spacer group Chemical group 0.000 description 6
- 230000037426 transcriptional repression Effects 0.000 description 6
- 238000010361 transduction Methods 0.000 description 6
- 230000026683 transduction Effects 0.000 description 6
- 102000011727 Caspases Human genes 0.000 description 5
- 108010076667 Caspases Proteins 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 102100036377 cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A Human genes 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- 210000004129 prosencephalon Anatomy 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- 241000589634 Xanthomonas Species 0.000 description 4
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 description 4
- 210000000234 capsid Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 238000013388 immunohistochemistry analysis Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001202 rhombencephalon Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 description 3
- 241000203069 Archaea Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 101710096438 DNA-binding protein Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101100441545 Drosophila melanogaster Cfp1 gene Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108060004795 Methyltransferase Proteins 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000006277 exogenous ligand Substances 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 238000001476 gene delivery Methods 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 239000000833 heterodimer Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 230000003955 neuronal function Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003523 substantia nigra Anatomy 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 230000010415 tropism Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- 108010013043 Acetylesterase Proteins 0.000 description 2
- 101001030716 Arabidopsis thaliana Histone deacetylase HDT1 Proteins 0.000 description 2
- 102000008682 Argonaute Proteins Human genes 0.000 description 2
- 108010088141 Argonaute Proteins Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000589875 Campylobacter jejuni Species 0.000 description 2
- 102000004018 Caspase 6 Human genes 0.000 description 2
- 108090000425 Caspase 6 Proteins 0.000 description 2
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 2
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 230000007018 DNA scission Effects 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 101000889905 Enterobacteria phage RB3 Intron-associated endonuclease 3 Proteins 0.000 description 2
- 101000889904 Enterobacteria phage T4 Defective intron-associated endonuclease 3 Proteins 0.000 description 2
- 101000889900 Enterobacteria phage T4 Intron-associated endonuclease 1 Proteins 0.000 description 2
- 101000889899 Enterobacteria phage T4 Intron-associated endonuclease 2 Proteins 0.000 description 2
- 241000589599 Francisella tularensis subsp. novicida Species 0.000 description 2
- 241000713813 Gibbon ape leukemia virus Species 0.000 description 2
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 description 2
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 description 2
- 101000687346 Homo sapiens PR domain zinc finger protein 2 Proteins 0.000 description 2
- 101000880098 Homo sapiens Sushi repeat-containing protein SRPX Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 108010061833 Integrases Proteins 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 101100219625 Mus musculus Casd1 gene Proteins 0.000 description 2
- 101001030698 Mus musculus Huntingtin Proteins 0.000 description 2
- 108091061960 Naked DNA Proteins 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100024885 PR domain zinc finger protein 2 Human genes 0.000 description 2
- 241000606856 Pasteurella multocida Species 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700040121 Protein Methyltransferases Proteins 0.000 description 2
- 102000055027 Protein Methyltransferases Human genes 0.000 description 2
- 230000004570 RNA-binding Effects 0.000 description 2
- 101100087805 Ralstonia solanacearum rip19 gene Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 241000589499 Thermus thermophilus Species 0.000 description 2
- 101710183280 Topoisomerase Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 101150055766 cat gene Proteins 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 108010050663 endodeoxyribonuclease CreI Proteins 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000037433 frameshift Effects 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000012212 insulator Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000009126 molecular therapy Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000478 neocortex Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 108010040003 polyglutamine Proteins 0.000 description 2
- 229920000155 polyglutamine Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004845 protein aggregation Effects 0.000 description 2
- 102000021127 protein binding proteins Human genes 0.000 description 2
- 108091011138 protein binding proteins Proteins 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000006916 protein interaction Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000001718 repressive effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000001103 thalamus Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- VEPOHXYIFQMVHW-PVJVQHJQSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;(2s,3s)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 VEPOHXYIFQMVHW-PVJVQHJQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 102100033647 Activity-regulated cytoskeleton-associated protein Human genes 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 description 1
- 102100025492 CUGBP Elav-like family member 3 Human genes 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100028892 Cardiotrophin-1 Human genes 0.000 description 1
- 108700004991 Cas12a Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102100024300 Cryptic protein Human genes 0.000 description 1
- 101710185307 Cryptic protein Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 101710155335 DELLA protein SLR1 Proteins 0.000 description 1
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 1
- 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 1
- 102100024810 DNA (cytosine-5)-methyltransferase 3B Human genes 0.000 description 1
- 101710123222 DNA (cytosine-5)-methyltransferase 3B Proteins 0.000 description 1
- 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 101100049549 Enterobacteria phage P4 sid gene Proteins 0.000 description 1
- 101800001467 Envelope glycoprotein E2 Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 101000860092 Francisella tularensis subsp. novicida (strain U112) CRISPR-associated endonuclease Cas12a Proteins 0.000 description 1
- 102000048120 Galactokinases Human genes 0.000 description 1
- 108700023157 Galactokinases Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108050008753 HNH endonucleases Proteins 0.000 description 1
- 102000000310 HNH endonucleases Human genes 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 108091027305 Heteroduplex Proteins 0.000 description 1
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000914299 Homo sapiens CUGBP Elav-like family member 3 Proteins 0.000 description 1
- 101000916283 Homo sapiens Cardiotrophin-1 Proteins 0.000 description 1
- 101000931098 Homo sapiens DNA (cytosine-5)-methyltransferase 1 Proteins 0.000 description 1
- 101000968287 Homo sapiens Denticleless protein homolog Proteins 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 101000926140 Homo sapiens Gem-associated protein 2 Proteins 0.000 description 1
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
- 101000609277 Homo sapiens Inactive serine protease PAMR1 Proteins 0.000 description 1
- 101000615495 Homo sapiens Methyl-CpG-binding domain protein 3 Proteins 0.000 description 1
- 101001109800 Homo sapiens Pro-neuregulin-1, membrane-bound isoform Proteins 0.000 description 1
- 101000716750 Homo sapiens Protein SCAF11 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000701440 Homo sapiens Stanniocalcin-1 Proteins 0.000 description 1
- 101000759312 Homo sapiens Tetratricopeptide repeat protein 12 Proteins 0.000 description 1
- 101000723833 Homo sapiens Zinc finger E-box-binding homeobox 2 Proteins 0.000 description 1
- 101000788669 Homo sapiens Zinc finger MYM-type protein 2 Proteins 0.000 description 1
- 101000802101 Homo sapiens mRNA decay activator protein ZFP36L2 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102100039437 Inactive serine protease PAMR1 Human genes 0.000 description 1
- 102000012330 Integrases Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000006830 Luminescent Proteins Human genes 0.000 description 1
- 108010047357 Luminescent Proteins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 1
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 1
- 102100021291 Methyl-CpG-binding domain protein 3 Human genes 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101100046877 Oryza sativa subsp. japonica TRAB1 gene Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 102100035593 POU domain, class 2, transcription factor 1 Human genes 0.000 description 1
- 101710084414 POU domain, class 2, transcription factor 1 Proteins 0.000 description 1
- 101100440941 Petroselinum crispum CPRF1 gene Proteins 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101710150114 Protein rep Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000205156 Pyrococcus furiosus Species 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 101150065817 ROM2 gene Proteins 0.000 description 1
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 1
- 241000589771 Ralstonia solanacearum Species 0.000 description 1
- 101100272715 Ralstonia solanacearum (strain GMI1000) brg11 gene Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 101710152114 Replication protein Proteins 0.000 description 1
- 102000003661 Ribonuclease III Human genes 0.000 description 1
- 108010057163 Ribonuclease III Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241001578339 Russula vesicatoria Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235346 Schizosaccharomyces Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 101001126150 Solanum lycopersicum Probable aquaporin PIP-type pTOM75 Proteins 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 102100030511 Stanniocalcin-1 Human genes 0.000 description 1
- 102400000096 Substance P Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 101800001271 Surface protein Proteins 0.000 description 1
- 102100037352 Sushi repeat-containing protein SRPX Human genes 0.000 description 1
- 102100023284 Tetratricopeptide repeat protein 12 Human genes 0.000 description 1
- 241001162933 Therophilus Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 102100028458 Zinc finger E-box-binding homeobox 2 Human genes 0.000 description 1
- 230000004598 abnormal eye movement Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000026925 anterograde axon cargo transport Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 241000617156 archaeon Species 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 238000000749 co-immunoprecipitation Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 102000055650 human NRG1 Human genes 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 102100034703 mRNA decay activator protein ZFP36L2 Human genes 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008172 membrane trafficking Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108010000222 polyserine Proteins 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001686 pro-survival effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 229950000659 remacemide Drugs 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000009844 retrograde axon cargo transport Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002924 silencing RNA Substances 0.000 description 1
- 230000004599 slow eye movement Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000021595 spermatogenesis Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000007100 striatal neurodegeneration Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962792701P | 2019-01-15 | 2019-01-15 | |
| US62/792,701 | 2019-01-15 | ||
| PCT/US2020/013661 WO2020150338A1 (en) | 2019-01-15 | 2020-01-15 | Htt repressors and uses thereof |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022517988A JP2022517988A (ja) | 2022-03-11 |
| JP2022517988A5 JP2022517988A5 (https=) | 2023-01-25 |
| JPWO2020150338A5 JPWO2020150338A5 (https=) | 2023-01-25 |
| JP7542912B2 true JP7542912B2 (ja) | 2024-09-02 |
Family
ID=71614037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540305A Active JP7542912B2 (ja) | 2019-01-15 | 2020-01-15 | Ｈｔｔリプレッサーおよびその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220064237A1 (https=) |
| EP (1) | EP3911349A4 (https=) |
| JP (1) | JP7542912B2 (https=) |
| CN (1) | CN113301909B (https=) |
| WO (1) | WO2020150338A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019204457A1 (en) | 2018-04-18 | 2019-10-24 | Sangamo Therapeutics, Inc. | Zinc finger protein compositions for modulation of huntingtin (htt) |
| CN115487315B (zh) * | 2022-04-20 | 2023-08-04 | 暨南大学 | 治疗亨廷顿病的药物 |
| WO2025004001A1 (en) * | 2023-06-30 | 2025-01-02 | Takeda Pharmaceutical Company Limited | Htt repressors and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013500045A (ja) | 2009-07-28 | 2013-01-07 | サンガモ バイオサイエンシーズ， インコーポレイテッド | トリヌクレオチド反復疾患を治療するための方法および組成物 |
| JP2015509958A (ja) | 2012-02-29 | 2015-04-02 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ハンチントン病を治療するための方法および組成物 |
| JP2018532428A (ja) | 2015-09-23 | 2018-11-08 | サンガモ セラピューティクス， インコーポレイテッド | Ｈｔｔリプレッサー及びその使用 |
| JP2021521775A (ja) | 2018-04-18 | 2021-08-30 | サンガモ セラピューティクス， インコーポレイテッド | ハンチンチン（ｈｔｔ）の調節のためのジンクフィンガータンパク質組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7888121B2 (en) * | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7972854B2 (en) * | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| JP5266210B2 (ja) * | 2006-05-25 | 2013-08-21 | サンガモ バイオサイエンシズ インコーポレイテッド | 改変開裂ハーフドメイン |
| WO2015070212A1 (en) * | 2013-11-11 | 2015-05-14 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| CN106459894B (zh) * | 2014-03-18 | 2020-02-18 | 桑格摩生物科学股份有限公司 | 用于调控锌指蛋白表达的方法和组合物 |
| RU2691102C2 (ru) * | 2014-05-08 | 2019-06-11 | Сангамо Байосайенсиз, Инк. | Способы и композиции для лечения болезни хантингтона |
| GB2544270A (en) * | 2015-11-05 | 2017-05-17 | Fundació Centre De Regulació Genòmica | Nucleic acids, peptides and methods |
-
2020
- 2020-01-15 EP EP20740948.3A patent/EP3911349A4/en active Pending
- 2020-01-15 CN CN202080009478.4A patent/CN113301909B/zh active Active
- 2020-01-15 JP JP2021540305A patent/JP7542912B2/ja active Active
- 2020-01-15 US US17/423,063 patent/US20220064237A1/en active Pending
- 2020-01-15 WO PCT/US2020/013661 patent/WO2020150338A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013500045A (ja) | 2009-07-28 | 2013-01-07 | サンガモ バイオサイエンシーズ， インコーポレイテッド | トリヌクレオチド反復疾患を治療するための方法および組成物 |
| JP2015509958A (ja) | 2012-02-29 | 2015-04-02 | サンガモ バイオサイエンシーズ， インコーポレイテッド | ハンチントン病を治療するための方法および組成物 |
| JP2018532428A (ja) | 2015-09-23 | 2018-11-08 | サンガモ セラピューティクス， インコーポレイテッド | Ｈｔｔリプレッサー及びその使用 |
| JP2021521775A (ja) | 2018-04-18 | 2021-08-30 | サンガモ セラピューティクス， インコーポレイテッド | ハンチンチン（ｈｔｔ）の調節のためのジンクフィンガータンパク質組成物 |
Non-Patent Citations (2)
| Title |
|---|
| Gabriela Ecco， A tale of domestication: the endovirome, its polydactyl controllers and the species-specificity of human biology，Development.，2017年，144，2719-29 |
| Zeitler, Bryan，Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington's disease，Nature Medicine，2019年，25，1131-42 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3911349A1 (en) | 2021-11-24 |
| WO2020150338A1 (en) | 2020-07-23 |
| EP3911349A4 (en) | 2023-01-18 |
| US20220064237A1 (en) | 2022-03-03 |
| CN113301909B (zh) | 2025-01-28 |
| JP2022517988A (ja) | 2022-03-11 |
| CN113301909A (zh) | 2021-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12551575B2 (en) | Htt repressors and uses thereof | |
| US11110154B2 (en) | Methods and compositions for treating Huntington's Disease | |
| JP7381476B2 (ja) | 希少疾患の処置のための方法および組成物 | |
| KR20210069692A (ko) | 조작된 유전자 조정제 | |
| US20250268981A1 (en) | Methods and compositions for modulation of tau proteins | |
| US12043650B2 (en) | Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (CFTR) gene | |
| CN110214184A (zh) | τ蛋白调节剂以及用于其递送的方法和组合物 | |
| JP7542912B2 (ja) | Ｈｔｔリプレッサーおよびその使用 | |
| HK1232141B (zh) | 用於治療亨廷頓病的方法和組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20211209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230113 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231221 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240321 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240705 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240801 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240816 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7542912 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |